TABLE 2.

Comparison of antibody reactivitiesa for JEV WT and mutant VLPs

MutationVirus titera
PolyclonebGroupSubgroupComplexSubcomplexType
MHIAF (JEV)c6B6C-1 (SLEV)4G2 (DENV2)23-1 (WNV)23-2 (JEV)5-2 (JEV)2B5B-3 (SLEV)6B4A-10 (JEV)16 (JEV)1B5D-1 (SLEV)J3 14 H5-2 (JEV)
None4.96.3≥6.8≥6.8≥6.85.4≥6.84.95.95.43.0
G104Hd4.4<3.0 4.9 6.36.3 3.9 6.34.4 3.9 4.9<3.0
G106Q4.9<3.0<3.0≥6.8≥6.8 3.0 3.5 5.9 6.3 3.0 3.0
G106K4.9 4.9 4.0 ≥6.8≥6.8 3.5 <3.05.46.3<3.03.0
G106V4.4<3.0<3.0≥6.8 5.9 <3.0 5.9 4.95.9<3.03.0
G106D4.9<3.0 3.0 ≥6.8≥6.8<3.0 3.0 5.46.3<3.03.0
L107R4.9≥6.8<3.0<3.06.3<3.0 4.9 5.9 6.35.93.5
L107D4.95.4<3.0 3.0 4.9 <3.0≥6.8 5.9 6.35.93.9
L107H4.46.3<3.0 5.4 5.9 <3.0≥6.85.45.95.43.5
L107Ae4.9≥6.8 3.0 6.36.3<3.0≥6.85.46.35.93.9
L107G4.9≥6.8<3.0 5.4 5.9 <3.0≥6.8 5.9 5.95.93.5
L107F4.4 4.4 <3.0 4.9 5.9 <3.0 5.9 3.5 4.4 3.9 3.0
  • a Ag-ELISA was used to determine the reciprocal end point titers (log10) for secreted VLP antigens. The numbers shown in boldface are the end point titers decreased below that of the WT by at least two threefold dilutions; the numbers in boldface italic are the titers increased over that of the WT by at least two threefold dilutions.

  • b Group, recognized by all flaviviruses examined; subgroup, recognized by more than one serocomplex; complex, recognized by all members of JEV complex; subcomplex, not recognized by all members of the serocomplex; type, recognized by JEV only.

  • c Virus against which antibody was raised.

  • d The G104H substitution prevented VLP secretion from transformed COS-1 cells at 37°C, but not at 28°C.

  • e The L107A mutation was obtained unintentionally due to misincorporation of sequence during the mutagenesis procedure.